Cargando…
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
BACKGROUND: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alt...
Autores principales: | Basedau, Hauke, Sturm, Lisa-Marie, Mehnert, Jan, Peng, Kuan-Po, Schellong, Marlene, May, Arne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126581/ https://www.ncbi.nlm.nih.gov/pubmed/35604755 http://dx.doi.org/10.7554/eLife.77146 |
Ejemplares similares
-
High-Density Electroencephalography-Informed Multiband Functional Magnetic Resonance Imaging Reveals Rhythm-Specific Activations Within the Trigeminal Nociceptive Network
por: Basedau, Hauke, et al.
Publicado: (2022) -
Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura
por: Peng, Kuan-Po, et al.
Publicado: (2021) -
Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021) -
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)